Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
Open Access
- 23 May 2023
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 37 (6), e22995
- https://doi.org/10.1096/fj.202300040r
Abstract
Immuno-oncology (IO)-based therapies such as checkpoint inhibitors, bi-specific antibodies, and CAR-T-cell therapies have shown significant success in the treatment of several cancer indications. However, these therapies can result in the development of severe adverse events, including cytokine release syndrome (CRS). Currently, there is a paucity of in vivo models that can evaluate dose-response relationships for both tumor control and CRS-related safety issues. We tested an in vivo PBMC humanized mouse model to assess both treatment efficacy against specific tumors and the concurrent cytokine release profiles for individual human donors after treatment with a CD19xCD3 bispecific T-cell engager (BiTE). Using this model, we evaluated tumor burden, T-cell activation, and cytokine release in response to bispecific T-cell-engaging antibody in humanized mice generated with different PBMC donors. The results show that PBMC engrafted NOD-scid Il2rg(null) mice lacking expression of mouse MHC class I and II (NSG-MHC-DKO mice) and implanted with a tumor xenograft predict both efficacy for tumor control by CD19xCD3 BiTE and stimulated cytokine release. Moreover, our findings indicate that this PBMC-engrafted model captures variability among donors for tumor control and cytokine release following treatment. Tumor control and cytokine release were reproducible for the same PBMC donor in separate experiments. The PBMC humanized mouse model described here is a sensitive and reproducible platform that identifies specific patient/cancer/therapy combinations for treatment efficacy and development of complications.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI132963)
This publication has 51 references indexed in Scilit:
- Cytokine release assays: Current practices and future directionsCytokine, 2014
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood, 2013
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood, 2012
- Mice, men and the relatives: cross-species studies underpin innate immunityOpen Biology, 2012
- Rituximab and Cytokine Release SyndromeCase Reports in Oncology, 2012
- Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsLeukemia Research, 2009
- Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complexClinical and Experimental Immunology, 2009
- Obtaining Human Peripheral Blood CellsCurrent Protocols in Immunology, 1997
- Hybrid antibodies can target sites for attack by T cellsNature, 1985